{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:06:34Z","timestamp":1784696794006,"version":"3.55.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tirofiban, a glycoprotein IIb\/IIIa receptor inhibitor, has shown promise in acute ischemic stroke (AIS) without medium- or large-vessel occlusion. The RESCUE BT2 trial demonstrated improved functional outcomes with IV tirofiban versus aspirin, but was conducted predominantly in Han Chinese populations, limiting generalizability to U.S. practice. This study evaluated the safety, operational feasibility, and exploratory clinical associations of a RESCUE BT2-based tirofiban protocol at a U.S. comprehensive stroke center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective single-center cohort study compared patients treated with tirofiban per RESCUE BT2 protocol (Nov 2023\u2013June 2025) with a historical standard care cohort meeting similar eligibility criteria (Jan 2021\u2013Oct 2023). Primary outcomes focused on safety, including any intracranial hemorrhage (ICH), symptomatic ICH, extracranial bleeding, thrombocytopenia, and mortality. Exploratory clinical outcomes included NIHSS trajectories, discharge modified Rankin Scale (mRS), discharge disposition, hospital length of stay, and available 90-day mRS. Multivariate regression models adjusted for baseline severity, early therapies, and neurological severity at the clinical decision point. Propensity score matching and\/or multiple imputation were conducted as sensitivity analyses, and the results were interpreted as exploratory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy-four patients were included (32 tirofiban, 42 standard care). No patients in the tirofiban group developed symptomatic or asymptomatic ICH, and no thrombocytopenia was observed. Extracranial bleeding occurred in 3 patients (9.4%). In adjusted exploratory analyses, tirofiban was associated with lower discharge NIHSS (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u202f=\u202f\u22122.199; 95% CI, \u22123.850 to \u22120.548;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.011), greater NIHSS improvement from the decision point to discharge (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u202f=\u202f2.815; 95% CI, 1.173\u20134.456;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.001), and a favorable shift in discharge mRS (OR 0.274; 95% CI, 0.087\u20130.86;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.027). In propensity-matched analysis, the direction of effect for discharge mRS was consistent but did not reach statistical significance. 90-day mRS analyses were limited by substantial differential missingness; complete-case and propensity-matched analyses were non-significant, and multiple-imputation results were sensitive to model assumptions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Implementation of a RESCUE BT2-based IV tirofiban protocol in a U.S. comprehensive stroke center was feasible and demonstrated a favorable safety profile in carefully selected AIS patients. Exploratory associations with improved neurological trajectories warrant prospective evaluation in larger multicenter studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1768603","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:48:39Z","timestamp":1784695719000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world experience with RESCUE BT2 tirofiban protocol versus standard care for select patients with acute ischemic stroke at a United States comprehensive stroke center: a single-center retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"Supreet","family":"Kaur","sequence":"first","affiliation":[{"name":"Department of Neurology, Barrow Neurological Institute","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Dang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Barrow Neurological Institute","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Barrow Neurological Institute","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassu Mehari","family":"Beyene","sequence":"additional","affiliation":[{"name":"Department of Neurology, Barrow Neurological Institute","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Nicholas","sequence":"additional","affiliation":[{"name":"Department of Neurology, Barrow Neurological Institute","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Tyler","family":"Haller","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Barrow Neurological Institute","place":["Phoenix, AZ, United States"]},{"name":"Department of Pharmacy, St. Joseph\u2019s Hospital and Medical Center","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Franzen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Barrow Neurological Institute","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Harnoor","sequence":"additional","affiliation":[{"name":"Department of Neurology, Barrow Neurological Institute","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracie","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Department of Neurology, Barrow Neurological Institute","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha","family":"Qaiser","sequence":"additional","affiliation":[{"name":"Department of Neurology, Barrow Neurological Institute","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhant","family":"Arora","sequence":"additional","affiliation":[{"name":"Department of Neurology, Barrow Neurological Institute","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Smitt","sequence":"additional","affiliation":[{"name":"Department of Neurology, Barrow Neurological Institute","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbi","family":"Heater","sequence":"additional","affiliation":[{"name":"Department of Neurology, Barrow Neurological Institute","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"May","sequence":"additional","affiliation":[{"name":"Department of Neurology, Duke University School of Medicine","place":["Durham, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josiah","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Barrow Neurological Institute","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Honor Health: Arizona State University John Shufeldt School of Medicine and Medical Engineering","place":["Tempe, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1161\/CIR.0000000000001412","article-title":"2026 Heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"153","author":"Palaniappan","year":"2026","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000513","article-title":"2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association\/American Stroke Association","author":"Prabhakaran","year":"2026","journal-title":"Stroke"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S1474-4422(12)70057-1","article-title":"Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial","volume":"11","author":"Walter","year":"2012","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1136\/jnnp-2014-308327","article-title":"Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke: a systematic review with pathophysiological implications","volume":"86","author":"Seners","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"17562864221147743","DOI":"10.1177\/17562864221147743","article-title":"Early neurological deterioration in patients with acute ischemic stroke: a prospective multicenter cohort study","volume":"16","author":"Liu","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/17474930241273685","article-title":"Early neurological deterioration in acute lacunar ischemic stroke: systematic review of incidence, mechanisms, and prospects for treatment","volume":"20","author":"Werring","year":"2025","journal-title":"Int J Stroke"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.10.010","article-title":"The etiologies of early neurological deterioration after thrombolysis and risk factors of ischemia progression","volume":"25","author":"Kim","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e2178","DOI":"10.1212\/WNL.0000000000010603","article-title":"Neurologic deterioration in patients with acute ischemic stroke or transient ischemic attack","volume":"95","author":"Park","year":"2020","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jns.2007.12.014","article-title":"Neurological deterioration in small vessel disease may be associated with increase of infarct volume","volume":"269","author":"Terasawa","year":"2008","journal-title":"J Neurol Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1212\/WNL.59.6.862","article-title":"Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator","volume":"59","author":"Alexandrov","year":"2002","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1161\/01.STR.0000170711.43405.81","article-title":"Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke","volume":"36","author":"Rubiera","year":"2005","journal-title":"Stroke"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0006-8993(01)02735-4","article-title":"Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion","volume":"912","author":"Zhang","year":"2001","journal-title":"Brain Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/jcbfm.2013.77","article-title":"Failure of collateral blood flow is associated with infarct growth in ischemic stroke","volume":"33","author":"Campbell","year":"2013","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"105885","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105885","article-title":"Early neurological deterioration and Hypoperfusion volume ratio on arterial spin labeling in patients with acute ischemic stroke","volume":"30","author":"Zhang","year":"2021","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4103\/bc.bc_68_21","article-title":"Neurological deterioration and computed tomography perfusion changes with increased time to peak in lacunar stroke","volume":"8","author":"Farooqui","year":"2022","journal-title":"Brain Circ"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12883-024-03825-7","article-title":"Rescue therapy of early neurological deterioration in lacunar stroke","volume":"24","author":"Park","year":"2024","journal-title":"BMC Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1080737","DOI":"10.3389\/fimmu.2022.1080737","article-title":"Neuroinflammation and brain-peripheral interaction in ischemic stroke: a narrative review","volume":"13","author":"Cheng","year":"2023","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1161\/01.STR.30.12.2631","article-title":"Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European cooperative acute stroke study (ECASS) I","volume":"30","author":"D\u00e1valos","year":"1999","journal-title":"Stroke"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1182\/bloodadvances.2020002888","article-title":"Platelets as drivers of ischemia\/reperfusion injury after stroke","volume":"5","author":"Shaik","year":"2021","journal-title":"Blood Adv"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s40265-025-02222-9","article-title":"Tirofiban in acute ischemic stroke: mechanistic rationale, clinical advances, and emerging therapeutic strategies","volume":"85","author":"Jiang","year":"2025","journal-title":"Drugs"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction","volume":"338","year":"1998","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1161\/STROKEAHA.110.599662","article-title":"Safety of tirofiban in acute ischemic stroke: the SaTIS trial","volume":"42","author":"Siebler","year":"2011","journal-title":"Stroke"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1161\/STROKEAHA.119.026240","article-title":"Low-dose tirofiban treatment improves neurological deterioration outcome after intravenous thrombolysis","volume":"50","author":"Wu","year":"2019","journal-title":"Stroke"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1161\/STROKEAHA.116.014413","article-title":"Safety and preliminary efficacy of early Tirofiban treatment after Alteplase in acute ischemic stroke patients","volume":"47","author":"Li","year":"2016","journal-title":"Stroke"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2503678","article-title":"ASSET-IT investigators. Early Tirofiban infusion after intravenous thrombolysis for stroke","volume":"393","author":"Tao","year":"2025","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1111\/jcpt.13816","article-title":"The efficacy and safety of intravenous tirofiban in the treatment of acute ischemic stroke patients with early neurological deterioration","volume":"47","author":"Du","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1001\/jamaneurol.2024.0868","article-title":"Et al; TREND investigators. Effects of Tirofiban on neurological deterioration in patients with acute ischemic stroke: a randomized clinical trial","volume":"81","author":"Zhao","year":"2024","journal-title":"JAMA Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1056\/NEJMoa2214299","article-title":"RESCUE BT2 investigators. Tirofiban for stroke without large or medium-sized vessel occlusion","volume":"388","author":"Zi","year":"2023","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"785836","DOI":"10.3389\/fneur.2021.785836","article-title":"Efficacy and safety of Tirofiban in clinical patients with acute ischemic stroke","volume":"8","author":"Han","year":"2022","journal-title":"Front Neurol"},{"key":"ref30","first-page":"543","article-title":"Effect of intravenous tirofiban vs placebo before endovascular thrombectomy on functional outcomes in large vessel occlusion stroke: the RESCUE BT randomized clinical trial","volume-title":"JAMA","author":"Qiu","year":"2022"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"108602","DOI":"10.1016\/j.clineuro.2024.108602","article-title":"Efficacy and safety of intravenous tirofiban versus standard medical treatment in acute ischemic stroke: a meta-analysis of randomized controlled trials","volume":"247","author":"Monteiro","year":"2024","journal-title":"Clin Neurol Neurosurg"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/bmj.39339.610000.BE","article-title":"The declaration of Helsinki","volume":"335","author":"Goodyear","year":"2007","journal-title":"BMJ"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(98)08020-9","article-title":"Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)","volume":"352","author":"Hacke","year":"1998","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0140-6736(07)60149-4","article-title":"SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study","volume":"369","author":"Wahlgren","year":"2007","journal-title":"Lancet"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1161\/01.str.20.7.864","article-title":"Measurements of acute cerebral infarction: a clinical examination scale","volume":"20","author":"Brott","year":"1989","journal-title":"Stroke"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","article-title":"Interobserver agreement for the assessment of handicap in stroke patients","volume":"19","author":"van Swieten","year":"1988","journal-title":"Stroke"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1518685","DOI":"10.3389\/fstro.2025.1518685","article-title":"Early neurological deterioration following acute stroke: association with reperfusion therapies and National Institutes of Health stroke scale score","volume":"4","author":"Yu","year":"2025","journal-title":"Front Stroke"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1097\/PHM.0000000000000502","article-title":"How do recurrent and first-ever strokes differ in rehabilitation outcomes?","volume":"95","author":"Ng","year":"2016","journal-title":"Am J Phys Med Rehabil"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e72658","DOI":"10.7759\/cureus.72658","article-title":"Impact of recurrence on functional Independence in stroke patients treated in a convalescent rehabilitation hospital","volume":"16","author":"Kanata","year":"2024","journal-title":"Cureus"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1768603\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:48:46Z","timestamp":1784695726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1768603\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":42,"alternative-id":["10.3389\/fneur.2026.1768603"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1768603","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1768603"}}